Iridian Asset Management’s Immuneering IMRX Stock Holding History

Iridian Asset Management’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-275,086	Closed	-$1.93M	–	45
2025 Q3	$1.93M	Buy	+275,086	New	+$1.43M	0.76%	34

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

EAM

Empery Asset Management New York $83M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Iridian Asset Management's IMRX Position: Q4 2025 in Review

Iridian Asset Management sold out of Immuneering (IMRX) in Q4 2025, closing a stake of 275,086 shares — an estimated $1.93M sold.

Iridian Asset Management first reported a position in IMRX in Q3 2025 and held it in 1 quarter. The position peaked at $1.93M in Q3 2025. 86 funds tracked by Wall St. Rank hold IMRX as of Q4 2025.

Iridian Asset Management reported no remaining Immuneering position as of Q4 2025 after selling out during the quarter.
Iridian Asset Management sold 275,086 Immuneering shares in Q4 2025, an estimated $1.93M.
Iridian Asset Management first reported a position in Immuneering in Q3 2025 and held it in 1 quarter.
Iridian Asset Management's Immuneering position peaked at $1.93M in Q3 2025.
86 funds tracked by Wall St. Rank held Immuneering as of Q4 2025.

Based on Iridian Asset Management's 13F filing for Q4 2025, filed 23 Jan 2026.